Immutep Ltd

Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma

Immutep receives FDA ODD for Efti in Soft Tissue Sarcoma

Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases

Update on Phase I Study of IMP761 for Autoimmune Diseases